NeuroPace, Inc. (NPCE): Price and Financial Metrics Recent IPO


NeuroPace, Inc. (NPCE): $17.42

-0.33 (-1.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NPCE Stock Price Chart Interactive Chart >

Price chart for NPCE

NPCE Price/Volume Stats

Current price $17.42 52-week high $27.38
Prev. close $17.75 52-week low $17.02
Day low $17.02 Volume 126,600
Day high $17.79 Avg. volume 106,502
50-day MA $21.61 Dividend yield N/A
200-day MA $0.00 Market Cap 423.24M

NeuroPace, Inc. (NPCE) Company Bio


NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.


NPCE Latest News Stream


Event/Time News Detail
Loading, please wait...

NPCE Latest Social Stream


Loading social stream, please wait...

View Full NPCE Social Stream

Latest NPCE News From Around the Web

Below are the latest news stories about NeuroPace Inc that investors may wish to consider to help them evaluate NPCE as an investment opportunity.

Global Artificial Neuroprosthetics Market 2021 Study Analysis: Rising Applications in Various Industries Boost the industry 2028| Cochlear, Abbott, Neuropace, Medtronic, Boston Scientific, Sonova

Report Title Artificial Neuroprosthetics Market is one of the most comprehensive and important additions to the QY Reports. Provides detailed research and analysis of key aspects of the global Artificial Neuroprosthetics market. Market analysts write in-depth information provided in this

OpenPR | September 8, 2021

Implantable Neurostimulation Devices Market Covering Growth Elements and Future Trends by 2027, Players - LivaNova, Nevro, NeuroPace, Beijing Pins, Synapse Biomedical, St. Jude Medical (Abbott)

The Implantable Neurostimulation Devices Market is expected to grow at a CAGR of 6.1 % and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020 The research report on the Implantable Neurostimulation Devices Market fabricated

OpenPR | August 27, 2021

Vagus Nerve Stimulators Market Anticipated to Observe the Maximum Growth During the Forecast Period, Players -Medtronic PLC LivaNova, PLC Neuropace Inc

New York, United States :The Research specialists at Decisive Markets Insights have crafted a brand-new report on the Vagus Nerve Stimulators MARKET market which will elucidate a 360-degree overview of the global market post-COVID-19 pandemic. Also, it will inculcate detailed

OpenPR | August 27, 2021

NeuroPace to Participate in Upcoming Conferences

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported that the company will be participating in three upcoming conferences.

Intrado Digital Media | August 23, 2021

NeuroPace, Inc. (NPCE) Q2 2021 Earnings Call Transcript

Joining me from NeuroPace are Mike Favet, CEO; and Rebecca Kuhn, CFO. Earlier today, NeuroPace released financial results for the quarter ended June 30, 2021. Before we begin, I'd like to remind you that management will make statements during this call that will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Yahoo | August 13, 2021

Read More 'NPCE' Stories Here

NPCE Price Returns

1-mo -10.71%
3-mo -28.87%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7594 seconds.